MedTrace Logo

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

NCT05189639 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2026-03-12

No results posted yet for this study

Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Mylotarg) for the potential treatment of acute myeloid leukemia (AML). AML is a disease that affects the body's white blood cells. This study is seeking participants in Korea who:

* Are 18 years of age or older
* Are adults and newly diagnosed with AML
* Currently receive Mylotarg for AML treatment in a hospital
* Are capable of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Participant's health will be closely monitored for any unwanted reactions during Mylotarg treatment. Disease progression will also be monitored. This will help determine if Mylotarg is safe to use and its effect on AML treatment.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05189639 on ClinicalTrials.gov